机构：[1]Oncology Center, The First AffiliatedHospital of Guangzhou University ofChinese Medicine, Guangzhou 510405,Guangdong, People’s Republic of China深圳市中医院深圳医学信息中心[2]Oncology Department, The SecondTraditional Chinese Medicine Hospital ofGuangdong Province, Guangzhou510405, Guangdong, People’s Republic ofChina[3]The Medical Department, 3DMedicines Inc, Shanghai 201114, People’sRepublic of China
第一作者机构：[1]Oncology Center, The First AffiliatedHospital of Guangzhou University ofChinese Medicine, Guangzhou 510405,Guangdong, People’s Republic of China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Xiao Z.,Huang X.,Xie B.,et al.Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(3):S665-S666.
APA：
Xiao, Z.,Huang, X.,Xie, B.,Xie, W.,Huang, M.&Lin, L..(2021).Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement.JOURNAL OF THORACIC ONCOLOGY,16,(3)
MLA：
Xiao, Z.,et al."Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement".JOURNAL OF THORACIC ONCOLOGY 16..3(2021):S665-S666
医学